Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AB1 | P08238 | 16/20 | 0.53 |
| ▸ | HSP90AA1 | P07900 | 15/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.51 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.51 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.48 |
| ▸ | TRAP1 | Q12931 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27863480 | 0.91 | HSP90AB1 (0.51) | HSP90AB1HSP90AA1HDAC6HDAC1HDAC4 | |
| SCHEMBL2098713 | 0.84 | HSP90AB1 (0.53) | HSP90AB1HSP90AA1HDAC6HDAC1HDAC4 | |
| SCHEMBL31058755 | 0.84 | HDAC6 (0.54) | HSP90AB1HSP90AA1HDAC6HDAC1HDAC4 | |
| SCHEMBL5023964 | 0.84 | CCNE1 (0.66) | HSP90AB1HSP90AA1 | |
| SCHEMBL5172274 | 0.82 | ADORA2A (0.55) | HSP90AB1HSP90AA1 | |
| SCHEMBL19245704 | 0.81 | HSP90AB1 (0.56) | HSP90AB1HSP90AA1HDAC6HDAC1HDAC4 | |
| SCHEMBL27854926 | 0.81 | CDK1 (0.71) | HSP90AB1HSP90AA1HDAC6HDAC1HDAC4 | |
| SCHEMBL24941702 | 0.81 | TK1 (0.60) | HSP90AB1HSP90AA1HDAC6HDAC1HDAC4 | |
| SCHEMBL4847394 | 0.81 | HSP90AB1 (0.53) | HSP90AB1HSP90AA1 | |
| SCHEMBL31187469 | 0.79 | HDAC6 (0.49) | HSP90AB1HSP90AA1HDAC6HDAC1HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108314685-B | Preparation method of 2-amino-6-chloro-9- (4-acetoxyl-3-acetoxymethyl butyl) purine | 上药康丽（常州）药业有限公司 | 2020-08-25 | — | — | CN | claimed |
| WO-2023176466-A1 | VIRUS DETECTION METHOD | 国立大学法人九州工業大学 | 2023-09-21 | — | — | WO | disclosed |
| CN-108314685-B | Preparation method of 2-amino-6-chloro-9- (4-acetoxyl-3-acetoxymethyl butyl) purine | 上药康丽（常州）药业有限公司 | 2020-08-25 | — | — | CN | disclosed |
| CN-108314685-B | Preparation method of 2-amino-6-chloro-9- (4-acetoxyl-3-acetoxymethyl butyl) purine | 上药康丽（常州）药业有限公司 | 2020-08-25 | — | — | CN | disclosed |
| CN-108484605-B | Preparation method of 2-amino-6-chloro-9- (4-acetoxyl-3-acetoxymethyl butyl) purine | 上药康丽（常州）药业有限公司 | 2020-08-21 | — | — | CN | disclosed |
| EP-1883639-B1 | PREPARATION OF FAMCICLOVIR AND OTHER PURINE DERIVATIVES | ARROW INT LTD (MT) | 2010-09-01 | — | — | EP | disclosed |
| EP-1883639-B1 | PREPARATION OF FAMCICLOVIR AND OTHER PURINE DERIVATIVES | ARROW INT LTD (MT) | 2010-09-01 | — | — | EP | disclosed |
| US-7601835-B2 | Preparation of famciclovir and other purine derivatives | ARROW INTERNATIONAL LIMITED (MT) | 2009-10-13 | — | — | US | disclosed |
| US-7601835-B2 | Preparation of famciclovir and other purine derivatives | ARROW INTERNATIONAL LIMITED (MT) | 2009-10-13 | — | — | US | disclosed |
| US-7601835-B2 | Preparation of famciclovir and other purine derivatives | ARROW INTERNATIONAL LIMITED (MT) | 2009-10-13 | — | — | US | disclosed |
| EP-1883639-A1 | PREPARATION OF FAMCICLOVIR AND OTHER PURINE DERIVATIVES | Arrow International Limited (MT) | 2008-02-06 | — | — | EP | disclosed |
| US-20060264629-A1 | Preparation of famciclovir and other purine derivatives | ARROW INTERNATIONAL LIMITED (MT) | 2006-11-23 | — | — | US | disclosed |
| WO-2006123175-A1 | PREPARATION OF FAMCICLOVIR AND OTHER PURINE DERIVATIVES | ARROW INTERNATIONAL LIMITED (MT) | 2006-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264629-A1 | Preparation of famciclovir and other purine derivatives | PNP, TYMP, DCTD | HSP90AB1 4605/4885HSP90AA1 4609/4885HDAC6 3872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.